NOT KNOWN FACTUAL STATEMENTS ABOUT ETOPOSIDE

Treatment with SR18662 noticeably decreases growth and proliferation of CRC cells. SR18662 displays enhanced efficacy in reducing viability of many CRC cell strains. Circulation cytometry Assessment adhering to SR18662 therapy exhibits a rise in cells captured in possibly S or G2/M phases in the cell cycle and a major boost in the amount of apoptot